Bristol Myers Squibb exercises option to initiate new program under the December 2020 agreement. Strategic collaboration combines ArsenalBio’s programmable cell therapy approach with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development.
The decision by Bristol Myers Squibb to expand our collaboration and add another program is a testament to the strength of our partnership and the promise of ArsenalBio’s proprietary technology.
Ken Drazan, MD, Co-Founder, Chairman, and Chief Executive Officer,
ArsenalBio.